High-Affinity CD16-polymorphism and Fc-Engineered Antibodies Enable Activity of CD16-chimeric Antigen Receptor-Modified T Cells for Cancer Therapy
British Journal of Cancer - United Kingdom
doi 10.1038/s41416-018-0341-1
Full Text
Open PDFAbstract
Available in full text
Date
November 15, 2018
Authors
Publisher
Springer Science and Business Media LLC